From Bench to Clinic: Advances in Anti‐Inflammatory Therapies for Atherosclerotic Coronary Artery Disease
The FASEB Journal · 30.09.2025 · 39 (18)
DOI: 10.1096/fj.202502269r ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 17.09.2025. Verfasst von Kan Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Coronary Artery Disease, Anti-Inflammatory Agents, Atherosclerosis, Inflammation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC), National Natural Science Foundation of China.
Abstract (Originalsprache)
Atherosclerosis (AS) is a chronic, progressive inflammatory disorder characterized by the deposition of lipid‐laden plaques, infiltration of immune cells, and remodeling of vascular structures within arterial walls. It remains the primary pathological driver of atherosclerotic coronary artery disease (ASCAD) and a major contributor to global mortality. While conventional lipid‐lowering therapies, particularly statins, have significantly reduced the incidence of ASCAD by targeting hyperlipidemia, a considerable residual inflammatory risk continues to exist. This unresolved inflammation exacerbates plaque vulnerability, increases the likelihood of rupture, and precipitates thrombotic complications. Recent breakthroughs in understanding the complex inflammatory mechanisms underlying AS, including endothelial dysfunction, macrophage polarization, T‐cell activation, and the release of pro‐inflammatory cytokines, have revealed novel therapeutic targets. This mechanistic insight has spurred the development of innovative anti‐inflammatory strategies, including monoclonal antibodies targeting specific cytokines (e.g., IL‐1β, TNF‐α), epigenetic modulators, and immune‐based interventions. This review synthesizes the current understanding of the inflammatory pathogenesis of AS, evaluates the translational potential of emerging anti‐inflammatory therapies, and discusses the challenges in optimizing the balance between efficacy and safety. By bridging discoveries in basic science with clinical applicability, this analysis aims to guide future research and foster therapeutic innovations in combating ASCAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- State Key Laboratory of Transvascular Implantation Devices, Hangzhou, China.
- Heart Regeneration and Repair Key Laboratory of Zhejiang Province, Hangzhou, China.
- Transvascular Implantation Devices Research Institute, Hangzhou, China.
- Binjiang Institute of Zhejiang University, Hangzhou, China.
ORCID-Profile: Lin Fan
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- National Natural Science Foundation of China
Zitieren
APA
Wang, K., Yin, Z., Zhang, Y., Wu, X., & Fan, L. (2025). From Bench to Clinic: Advances in Anti‐Inflammatory Therapies for Atherosclerotic Coronary Artery Disease. The FASEB Journal, 39(18). https://doi.org/10.1096/fj.202502269r
Vancouver
Wang K, Yin Z, Zhang Y, Wu X, Fan L. From Bench to Clinic: Advances in Anti‐Inflammatory Therapies for Atherosclerotic Coronary Artery Disease. The FASEB Journal. 2025;39(18). doi:10.1096/fj.202502269r
BibTeX
@article{Wang2025,
author = {Wang, Kan and Yin, Zheng and Zhang, Yang and Wu, Xianpeng and Fan, Lin},
title = {From Bench to Clinic: Advances in Anti‐Inflammatory Therapies for Atherosclerotic Coronary Artery Disease},
journal = {The FASEB Journal},
year = {2025},
volume = {39},
number = {18},
doi = {10.1096/fj.202502269r}
}
EUVIMED